(±)11-HETE-d8
(Synonyms: (±)11-Hydroxyeicosatetraenoic Acid-d8) 目录号 : GC46254
A neuropeptide with diverse biological activities
Cas No.:2750534-80-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
(±)11-HETE-d8 is intended for use as an internal standard for the quantification of (±)11-HETE by GC- or LC-MS. (±)11-HETE is an oxylipin formed non-enzymatically from arachidonic acid .1,2 Levels of (±)11-HETE are increased in an in vitro model of lipid peroxidation induced by ferrous ammonium sulfate (FAS) in rat brain homogenates.3 Levels are also increased in rat liver in an in vivo model of lipid peroxidation induced by carbon tetrachloride (CCl4). It has been found in skin extracts from individuals with psoriasis and in atherosclerotic plaques.4,5
1.Powell, W.S., and Rokach, J.Biosynthesis, biological effects, and receptors of hydroxyeicosatetraenoic acids (HETEs) and oxoeicosatetraenoic acids (oxo-ETEs) derived from arachidonic acidBiochim. Biophys. Acta1851(4)340-355(2014) 2.Derogis, P.B.M.C., Chaves-Filho, A.B., and Miyamoto, S.Characterization of hydroxy and hydroperoxy polyunsaturated fatty acids by mass spectrometryBioactive lipids in health and disease21-38(2019) 3.Guido, D.M., McKenna, R., and Mathews, W.R.Quantitation of hydroperoxy-eicosatetraenoic acids and hydroxy-eicosatetraenoic acids as indicators of lipid peroxidation using gas chromatography-mass spectrometryAnal. Biochem.209(1)123-129(1993) 4.Camp, R.D.R., Mallet, A.I., Woollard, P.M., et al.The identification of hydroxy fatty acids in psoriatic skinProstaglandins26(3)431-447(1983) 5.Waddington, E., Sienuarine, K., Puddey, I., et al.Identification and quantitation of unique fatty acid oxidation products in human atherosclerotic plaque using high-performance liquid chromatographyAnal. Biochem.292(2)234-244(2001)
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.0441 mL | 15.2207 mL | 30.4414 mL |
| 5 mM | 0.6088 mL | 3.0441 mL | 6.0883 mL |
| 10 mM | 0.3044 mL | 1.5221 mL | 3.0441 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。